Non-small cell lung cancer+1
Not yet recruitingStudy of Niraparib and Dostarlimab for Patients with Advanced Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma with Specific Genetic Mutations
Study of Niraparib and Dostarlimab for Patients with Advanced Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma with Specific Genetic Mutations
- Disease:Non-small cell lung cancerPleural mesothelioma
- Substances:DostarlimabNiraparib
Italy- Participants:18–64 years · 65+ years
- Substances:Dostarlimab
- Sponsor:Universita' Degli Studi Di Torino










